EPINEPHrine IV bags recalled for sterility assurance failure
Central Admixture Pharmacy Services recalled 554 bags of EPINEPHrine added to dextrose 5% IV bags nationwide due to insufficient validation of sanitization procedures, creating a lack of sterility assurance.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall of a sterility-critical injectable medication with inadequate sanitization validation. No illnesses or injuries reported, but the hazard presents a significant theoretical risk to patient safety.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling 554 bags of EPINEPHrine added to dextrose 5% (4mg/250ml, 16 mcg/mL) IV bags that were distributed nationwide in the USA. The product is supplied as prescription-only intravenous bags.
The recall was initiated because the manufacturer lacked validation data for sanitization cycles used in the preparation of these IV bags. This deficiency resulted in a lack of assurance of sterility for the affected product.
Healthcare providers with patients who have received or are using these IV bags should consult appropriate clinical protocols regarding any potential exposure. The affected lot numbers are 36-262162 and 36-262163, both expiring 10/5/2023.
The recalled product
- Product
- EPINEPHrine added to dextrose 5%, 4mg/250ml (16 mcg/mL), IV Bag, Rx Only, Central Admixture Pharmacy Services, Inc., 2200 South 43rd Avenue, Phoenix, AZ 85043, NDC: 72196-7018-1.
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Hazard
- sterility-failure
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot# 36-262162
- 36-262163
- Exp 10/5/2023.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27